Literature DB >> 31302624

Ototoxicity, a rare but reversible adverse effect of a commonly used antimicrobial agent.

Pawan Kumar Singh1, Vishal Sharma2.   

Abstract

In this case report, we describe a rare manifestation of amphotericin B (AMB) toxicity. A case of fever, hepato-splenomegaly and pancytopenia was diagnosed, based on serological test and demographic profile, as visceral leishmaniasis complicated with secondary haemophagocytic lymphohistiocytosis. He was managed with conventional AMB. Subsequently, patient was showing subjective and objective improvement. Suddenly after receiving 450 mg of cumulative dose of AMB, patient developed hearing loss. On evaluation, he was found to have bilateral mixed hearing loss. Patient was investigated for the causes of hearing loss. When nothing could be attributed as an aetiology, AMB was stopped (after 500 mg cumulative dose). After missing the dose of AMB, patient had a dramatic improvement in his sense of hearing, which was confirmed objectively by audiometry before and after the event. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  drugs: infectious diseases; infections; malignant and benign haematology; tropical medicine (infectious disease)

Mesh:

Substances:

Year:  2019        PMID: 31302624      PMCID: PMC6626447          DOI: 10.1136/bcr-2019-230251

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

Review 1.  Leishmaniasis: treatment updates and clinical practice guidelines review.

Authors:  Nathanial K Copeland; Naomi E Aronson
Journal:  Curr Opin Infect Dis       Date:  2015-10       Impact factor: 4.915

Review 2.  The kidney and ear: emerging parallel functions.

Authors:  Elena Torban; Paul Goodyer
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

3.  Neurological manifestations in a patient with visceral leishmaniasis.

Authors:  B Karak; R K Garg; S Misra; A M Sharma
Journal:  Postgrad Med J       Date:  1998-07       Impact factor: 2.401

4.  Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study.

Authors:  Elisabet Bergsten; AnnaCarin Horne; Maurizio Aricó; Itziar Astigarraga; R Maarten Egeler; Alexandra H Filipovich; Eiichi Ishii; Gritta Janka; Stephan Ladisch; Kai Lehmberg; Kenneth L McClain; Milen Minkov; Scott Montgomery; Vasanta Nanduri; Diego Rosso; Jan-Inge Henter
Journal:  Blood       Date:  2017-09-21       Impact factor: 22.113

Review 5.  Amphotericin B: side effects and toxicity.

Authors:  Rafael Laniado-Laborín; Maria Noemí Cabrales-Vargas
Journal:  Rev Iberoam Micol       Date:  2009-12-31       Impact factor: 1.044

Review 6.  Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function.

Authors:  Juan Pablo Botero Aguirre; Alejandra Maria Restrepo Hamid
Journal:  Cochrane Database Syst Rev       Date:  2015-11-23

7.  Injectable paromomycin for Visceral leishmaniasis in India.

Authors:  Shyam Sundar; T K Jha; Chandreshwar P Thakur; Prabhat K Sinha; Sujit K Bhattacharya
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

Review 8.  [Drug-induced benign intracranial hypertension. Apropos of a case with amphotericin B. Review of the literature].

Authors:  P Heudier; R M Chichmanian; B Taillan; N Gratecos; J G Fuzibet; P Dujardin
Journal:  Therapie       Date:  1992 Sep-Oct       Impact factor: 2.070

Review 9.  Hemophagocytic lymphohistiocytosis and visceral leishmaniasis in children: case report and systematic review of literature.

Authors:  Maria Scalzone; Antonio Ruggiero; Stefano Mastrangelo; Giovanna Trombatore; Vita Ridola; Palma Maurizi; Riccardo Riccardi
Journal:  J Infect Dev Ctries       Date:  2016-01-31       Impact factor: 0.968

10.  Reversible ototoxicity: a rare adverse reaction of liposomal amphotericin-B used for the treatment of antimony-resistant visceral leishmaniasis in an elderly male.

Authors:  Pc Das; Ramesh Kandel; Kapil Sikka; Ab Dey
Journal:  Clin Med Insights Case Rep       Date:  2014-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.